Diabetes drug shows promise in early cancer combo trial
NCT ID NCT02133625
First seen Apr 14, 2026 · Last updated May 12, 2026 · Updated 4 times
Summary
This early-phase trial tested the safety and best dose of combining the diabetes drug pioglitazone with the chemotherapy carboplatin in 14 people with advanced or metastatic solid tumors that could not be cured with standard treatments. The goal was to find the maximum tolerated dose and describe any side effects. The study also looked at whether pioglitazone changed how carboplatin works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.